Promedius , a startup developing artificial intelligence (AI) technology to prevent aging and metabolic diseases, announced on the 15th that it signed a business agreement (MOU) with the Korean Tuberculosis Association for the prevention and early detection of tuberculosis and osteoporosis.
Through this agreement, the two organizations plan to jointly develop an AI-based health screening service for vulnerable groups with low medical accessibility and apply it to the public health sector through a pilot project this year. In particular, they plan to jointly explore the possibility of utilizing it in public medical settings to respond to geriatric diseases that are increasing as we enter a super-aging society.
Promedius plans to apply its AI technology to tuberculosis screening for the elderly conducted by the Bokseongja Hospital and local governments, and also plans to use data held by the Korean Tuberculosis Association to advance AI performance and conduct related joint research.
The technology at the center of this agreement is the AI-based software 'Osteo Signal' developed by Promedius. This product analyzes chest X-ray images of patients over 50 years of age to screen for osteoporosis and assists medical staff in their diagnosis. Its main feature is that it captures subtle bone change signals and contributes to early diagnosis.
Promedius CEO Bae Hyun-jin said, “This agreement is a practical first step toward eliminating blind spots in public medical care,” and added, “We will contribute to the early detection of diseases in the elderly, such as osteoporosis, through AI technology.”
- See more related articles
You must be logged in to post a comment.